



*Atoms for Peace and Development*

الوكالة الدولية للطاقة الذرية

国际原子能机构

International Atomic Energy Agency

Agence internationale de l'énergie atomique

Международное агентство по атомной энергии

Organismo Internacional de Energía Atómica

Vienna International Centre, PO Box 100, 1400 Vienna, Austria

Phone: (+43 1) 2600 • Fax: (+43 1) 26007

Email: [Official.Mail@iaea.org](mailto:Official.Mail@iaea.org) • Internet: <https://www.iaea.org>

In reply please refer to: CN-288; EVT1904973

Dial directly to extension: (+43 1) 2600-21315

The Secretariat of the International Atomic Energy Agency (IAEA) is pleased to inform the non-governmental organizations receiving the present communication that the IAEA will hold the **International Conference on Advances in Radiation Oncology (ICARO-3)** (hereinafter referred to as “event”) at the IAEA’s Headquarters in Vienna, Austria, from **23 to 26 February 2021**.

The purpose of the event is to review the current developments in, and future prospects of, clinical, technological, and medical physics, as well as molecular/biological innovations, in radiation oncology, with a view to addressing the challenge of cancer management in Member States.

The event will be held in English.

The organizations receiving the present communication are invited to disseminate the attached Announcement and Call for Papers to the target audience for the event and to designate participants using Form A. Submissions of papers using Form B can only be considered if received by the deadline indicated in Section N of the Announcement and Call for Papers.

It should be noted that compensation is not payable by the IAEA for any damage to or loss of personal property. The IAEA also does not provide health insurance coverage for participants in events. Arrangements for private insurance coverage on an individual basis should therefore be made. The IAEA will, however, provide insurance coverage for accidents and illnesses that clearly result from any work performed for the IAEA.



2020-04-09

Enclosures: Announcement and Call for Papers

Participation Form (Form A)

Form for Submission of a Paper (Form B)





**IAEA**

International Atomic Energy Agency

*Atoms for Peace and Development*

# **International Conference on Advances in Radiation Oncology (ICARO-3)**

**IAEA Headquarters  
Vienna, Austria**

**23–26 February 2021**

**Organized by the  
International Atomic Energy Agency (IAEA)**

## **Announcement and Call for Papers**

### **A. Introduction**

The International Atomic Energy Agency (IAEA) is organizing the third International Conference on Advances in Radiation Oncology (ICARO-3), following the successes of the first and second conferences (ICARO-1 and ICARO-2), which were held in 2009 and 2017. The advances in radiotherapy in the last years have been striking, although numerous challenges remain, including achieving access to high standard cancer care in many countries. New radiotherapy techniques have been implemented in the past decades, including three-dimensional conformal therapy, stereotactic radiotherapy, intensity modulated radiation therapy, image guided and stereotactic body radiation therapy, tomotherapy, new brachytherapy and unsealed-source techniques, and proton and heavy ion therapy. The increased use of these complex techniques, coupled with the need to treat more patients in less time, will continue to drive a reliance on high-end technologies and impose a financial burden on

health care programmes. In addition, the development and implementation of quality assurance programmes for these new techniques pose major challenges in Member States.

The conference will give health care professionals an opportunity to review the current developments in clinical applications in the fields of radiation oncology, radiation biology and medical physics, with a view to addressing the challenges of appropriate cancer management in Member States.

It will also critically examine the pivotal role of emerging radiotherapy techniques in tackling the health challenges common to many Member States.

An appropriate number of accredited continuing medical education (CME) credits will be awarded to participants.

## **B. Objectives**

The conference is aimed at defining the current role and future potential of technological, medical physics and molecular/biological innovations for their incorporation into routine clinical practice in radiation oncology. It will also provide a forum where advances in technology, best practices and quality assurance methodologies can be disseminated and scientific knowledge exchanged. The conference will have the following specific objectives:

- To review the current role and future potential of technological, medical physics and molecular/biological innovations for clinical use in radiation oncology
- To explore the applications of improved imaging tools in treatment planning
- To review the current status of evidence-based recommendations for the treatment of common cancers
- To review the latest developments in medical dosimetry and dose auditing procedures for new radiotherapy techniques
- To review the current status of comprehensive audits in radiotherapy
- To review resource sparing approaches in clinical radiotherapy practice
- To exchange information on the current advances and implementation challenges in the field among leading experts
- To define future challenges and directions in the clinical use of radiotherapy

## **C. Format and Topics**

The conference programme will include plenary and parallel sessions, poster sessions, round-table discussions, lunch forums and teaching lectures.

The **plenary sessions** will include topics of interest to all participants such as personalized medicine, recent technological, physical and clinical developments, quality assurance, challenges and solutions, and health care economics.

**Parallel sessions** will cover detailed developments and recent findings related to clinical and physical aspects of radiotherapy.

**Poster sessions** will be dedicated to discussions and interactions with colleagues.

**Round-table discussions** will address specific challenges from different perspectives and **lunch forums** will review potential solutions to these challenges such as telemedicine and transitioning to paperless radiotherapy departments.

The **teaching lectures** will provide an opportunity for continuous professional development for all participants.

The IAEA invites participants to provide high quality contributions on all aspects of radiotherapy. The topics to be addressed during the conference will be centred on technological as well as biological, medical physics and clinical advances, and should consider real clinical settings in all Member States. Both academic and practice-based papers under the umbrella of the following topics will be considered:

- Technological advances and challenges
- Roadmap for setting up modern radiation oncology facilities
- New treatment and imaging techniques and clinical evidence
- Health economics in radiotherapy
- Developments in treatment planning
- Small field dosimetry
- Auditing procedures
- Personalized medicine
- Advances in the treatment of recurrent patients
- National cancer control strategies
- Developments in quality assurance and new approaches to quality management
- Safety in radiation therapy
- Intensity modulated radiotherapy, including arc-based approaches
- Image-guided radiotherapy
- Stereotactic body radiotherapy
- Particle therapy
- Telemedicine
- Radiobiology
- Spatially fractionated radiation therapy
- FLASH therapy
- Combined therapies
- Paediatric radiotherapy
- Clinical research
- Applied brachytherapy
- Education and training of professionals

## **D. Target Audience**

This conference will offer an opportunity to review the latest technological, clinical and biological developments that are relevant to radiotherapy, and the main target audience therefore comprises:

- Radiation oncologists
- Radiobiologists
- Medical physicists
- Technologists

The conference would also be of interest to scientists, researchers and biomedical engineers working in the field of radiotherapy.

## **E. Expected Outcomes**

The conference will provide clinicians, scientists and other professionals with an overview of technological achievements in the field of advanced radiotherapy techniques and of their potential future therapeutic benefits, as well as provide a summary of progress made in the molecular/biological modification of tumour and normal tissue responses, and of advances in medical physics. Also, the proceedings of the conference will document the impact of new technological and biological tools in current clinical practice and the likely future integration of the knowledge and tools in radiotherapy, preferably using clinical trials as a suitable matrix for providing robust data for future clinical implementation. A review of the effectiveness and limitations of the current quality assurance programmes will be completed and new innovative processes will be disseminated.

## **F. Papers**

Contributions on the topics listed in Section C above are welcome as oral or poster presentations. All submissions, apart from invited papers, must present original work and should not have been published elsewhere.

### **F.1. Submission of Synopses**

Synopses (up to two printed A4 pages, including not more than one figure, graph or table, no references) must be uploaded to the conference's web browser-based file submission system (IAEA-INDICO) which will be available on the conference web page (see Section P) from **9 April to 30 June 2020**. No other submission route will be accepted. Specifications for the layout will be available on IAEA-INDICO.

In addition, authors must electronically submit the following two forms to their appropriate governmental authority (see Section G) for transmission to the IAEA. These forms must be received by the IAEA no later than **31 July 2020**.

- Participation Form (Form A)
- Form for Submission of a Paper (Form B)

**IMPORTANT:** The uploaded synopses will be considered by the Programme Committee only if these two forms have been received by the IAEA through the established official channels (see Section G).

## F.2. Acceptance of Synopses

The Secretariat reserves the right to exclude synopses that do not comply with its technical or scientific quality standards and/or that do not apply to one of the topics in Section C above.

The number of contributions that can be accepted for oral presentation is limited. Authors who prefer to present their papers as posters are requested to indicate this preference on Form A and in INDICO, at the time of submitting their extended synopsis.

Authors will be notified by **31 August 2020** as to whether their submission has been accepted for presentation at the conference, either orally or as a poster.

## G. Participation and Registration

All persons wishing to participate in the conference must be designated by an IAEA Member State or should be members of organizations that have been invited to attend. The list of invited organizations will be available on the conference website (see Section P).

In order to be designated by an IAEA Member State, participants are requested to send the following form(s), as applicable, to their competent national authority (e.g. Ministry of Foreign Affairs, Permanent Mission to the IAEA or National Atomic Energy Authority):

- Participation Form (Form A): participation only; no deadline if only Form A is submitted.
- Form for Submission of a Paper (Form B): participants submitting a paper through INDICO must send the completed and signed Form B together with Form A to their competent national authority for onward transmission to the IAEA ([Official.Mail@iaea.org](mailto:Official.Mail@iaea.org)) by **31 July 2020**.
- Grant Application Form (Form C): participants requesting financial support from the IAEA, must complete Form C and send it together with Form A (and Form B, if applicable) to the competent national authority for onward transmission to the IAEA ([Official.Mail@iaea.org](mailto:Official.Mail@iaea.org)) by **31 July 2020**. Form C must be stamped and signed by the competent national authority.

Participants who are members of an organization invited to attend are requested to send the above form(s) through their organization to the IAEA ([Official.Mail@iaea.org](mailto:Official.Mail@iaea.org)).

In addition, participants are requested to pre-register online through the IAEA web page for the conference.

## H. Expenditures and Grants

No registration fee is charged to participants.

The IAEA is generally not in a position to bear the travel and other costs of participants in the conference. The IAEA has, however, limited funds at its disposal to help cover the cost of attendance of certain participants. Upon specific request, such assistance may be offered to normally one participant per country, provided that, in the IAEA's view, the participant will make an important contribution to the conference.

If Governments wish to apply for a grant on behalf of one of their participants, the Participation Form (Form A) and the Grant Application Form (Form C), stamped and signed by the Government, must reach the IAEA ([Official.Mail@iaea.org](mailto:Official.Mail@iaea.org)) by **31 July 2020**.

Applications that do not comply with the above conditions cannot be considered.

Approved grants will be issued in the form of a lump sum payment that might only **cover part of the cost of attendance**.

## **I. Distribution of Documents**

A preliminary programme of the conference will be made available on the conference web page (see Section P) before the start of the conference. The final programme and all accepted synopses will be available to all officially designated participants shortly before the conference.

## **J. Exhibitions**

A limited amount of space will be available for commercial vendors' displays/exhibits during the conference. Interested parties should contact the Scientific Secretariat by email: [icaro@iaea.org](mailto:icaro@iaea.org) by **31 July 2020**.

## **K. Working Language**

The working language of the conference will be English.

## **L. Venue and Accommodation**

The conference will be held at the IAEA's Headquarters in Vienna, Austria. Participants must make their own travel and accommodation arrangements. Hotels offering a reduced rate for participants are listed on <https://www.iaea.org/events>. Please note that the IAEA is not in a position to assist participants with hotel bookings, nor can the IAEA assume responsibility for paying fees for cancellations, re-bookings and no-shows.

## **M. Visas**

Participants who require a visa to enter Austria should submit the necessary application to the nearest diplomatic or consular representative of Austria as early as 3 months but not later than four weeks before their travel. Since Austria is a Schengen State, persons requiring a visa will have to apply for a Schengen visa. In States where Austria has no diplomatic mission, visas can be obtained from the consular authority of a Schengen Partner State representing Austria in the country in question.

For more information, please see the Austria Visa Information on <https://www.iaea.org/events>.



## N. Key Deadlines

Submission of synopses through IAEA-INDICO	<b>30 June 2020</b>
Submission of Form B (together with Form A) through official channels	<b>31 July 2020</b>
Submission of Form C (together with Form A) through official channels	<b>31 July 2020</b>
Notification of acceptance of extended synopsis for oral or poster presentation	<b>31 August 2020</b>
Submission of Form A only (no paper submission, no grant request)	<b>No deadline</b>

## O. Conference Secretariat

### General postal address and contact details of the IAEA:

International Atomic Energy Agency  
 Vienna International Centre  
 PO Box 100  
 1400 VIENNA  
 AUSTRIA  
 Tel.: +43 1 2600 0  
 Fax: +43 1 2600 7  
 Email: [Official.Mail@iaea.org](mailto:Official.Mail@iaea.org)

### Scientific Secretaries:

**Mr Eduardo Zubizarreta**  
 Applied Radiation Biology and Radiotherapy Section  
 Division of Human Health  
 Department of Nuclear Sciences and Applications  
 Tel.: +43 1 2600 21669

**Ms Debbie van der Merwe**  
 Dosimetry and Medical Radiation Physics Section  
 Division of Human Health  
 Department of Nuclear Sciences and Applications  
 Tel.: +43 1 2600 21653

**Email address of the Scientific Secretaries:** [icaro@iaea.org](mailto:icaro@iaea.org)

**Administration and organization:**

**Ms Martina Khaelss**

Conference Services Section

Division of Conference and Document Services

Department of Management

IAEA-CN-288; EVT1904973

Tel.: +43 1 2600 21315

Email: [M.Khaelss@iaea.org](mailto:M.Khaelss@iaea.org)

Subsequent correspondence on scientific matters should be sent to the Scientific Secretaries, and correspondence on administrative matters to the Conference Services Section.

## **P. Conference Web Page**

The IAEA web page for the conference is as follows:

<https://www.iaea.org/events/icaro-3>

It will be updated regularly with new information, and participants are encouraged to check it on a regular basis.

# Participation Form

## International Conference on Advances in Radiation Oncology (ICARO-3)

**IAEA Headquarters, Vienna, Austria**

**23–26 February 2021**

To be completed by the participant and sent to the competent official authority (e.g. Ministry of Foreign Affairs, Permanent Mission to the IAEA, or National Atomic Energy Authority) of his/her country for subsequent transmission to the International Atomic Energy Agency (IAEA), Vienna International Centre, PO Box 100, 1400 Vienna, Austria, either electronically by email to: [Official.Mail@iaea.org](mailto:Official.Mail@iaea.org) or by fax to: +43 1 26007 (no hard copies needed).

Participants who are members of an invited organization can submit this form to their organization for subsequent transmission to the IAEA.

Family name(s): (same as in passport)	First name(s): (same as in passport)	Mr/Ms
Institution:		
Full address:		
Tel:		
Email:		
Nationality:	Representing following Member State/non-Member State/entity or invited organization:	
Do you intend to submit a paper?                      Yes <input type="checkbox"/> No <input type="checkbox"/> Would you prefer to present your paper as a poster?    Yes <input type="checkbox"/> No <input type="checkbox"/> Title:		



# Form for Submission of a Paper

## International Conference on Advances in Radiation Oncology (ICARO-3)

**IAEA Headquarters, Vienna, Austria**

**23–26 February 2021**

To be completed by the participant and sent to the competent official authority (e.g. Ministry of Foreign Affairs, Permanent Mission to the IAEA, or National Atomic Energy Authority) of his/her country for subsequent transmission to the International Atomic Energy Agency (IAEA), Vienna International Centre, PO Box 100, 1400 Vienna, Austria, either electronically by email to: [Official.Mail@iaea.org](mailto:Official.Mail@iaea.org) or by fax to: +43 1 26007 (no hard copies needed).

Participants who are members of an invited organization can submit this form to their organization for subsequent transmission to the IAEA.

**Deadline for receipt by IAEA through official channels: 31 July 2020**

Title of the paper:		
Abstract id in IAEA-INDICO:		
Family name(s) and first name(s) of author(s): (same as in passport(s)) (if more than 3, please indicate them in INDICO)	Scientific establishment(s) in which the work has been carried out	City/Country
1.		
2.		
3.		
Family name(s) and first name(s) of author presenting the paper: (same as in passport)	Mr/Ms:	
Mailing address:		
Tel (Fax):		
Email:		

I hereby agree to assign to the International Atomic Energy Agency (IAEA):

- the copyright; or
- the non-exclusive, world-wide, free-of-charge licence (this option is only for those authors whose parent institution does not allow them to transfer the copyright for work carried out in that institution) granting the IAEA world rights for the use of the aforementioned material in this and any future editions of the publication, in all languages, and in all formats available now, or to be developed in the future (digital formats, hardcopy etc.).

**Please note:** If granting the licence mentioned above, please supply any copyright acknowledgement text required.

Furthermore, I herewith declare:

- that the material submitted to the IAEA is original, except for such excerpts from copyrighted works as may be included with the permission of the copyright holder thereof, has been written by the stated authors, has not been published before, and is not under consideration for publication by another entity;
- that any permissions and rights to publish required for third-party content, including but not limited to figures and tables, have been obtained, that all published material is correctly referenced; and
- that the material submitted to the IAEA does not contain any libellous or other unlawful statements and does not contain any materials that violate any personal or proprietary rights of any person or entity.

**Date:**

**Signature of main author:**